Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

Version 1 : Received: 15 January 2024 / Approved: 16 January 2024 / Online: 17 January 2024 (07:42:49 CET)

How to cite: Zhang, B.; Zhang, X.; Ito, M.; Yajima, S.; Yoshida, K.; Ohno, M.; Nishi, E.; Wang, H.; Li, S.; Kubota, M.; Yoshida, Y.; Matsutani, T.; Mine, S.; Machida, T.; Takemoto, M.; Yamagata, H.; Hayashi, A.; Yokote, K.; Kobayashi, Y.; Takizawa, H.; Kuroda, H.; Shimada, H.; Iwadate, Y.; Hiwasa, T. JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases. Preprints 2024, 2024011206. https://doi.org/10.20944/preprints202401.1206.v1 Zhang, B.; Zhang, X.; Ito, M.; Yajima, S.; Yoshida, K.; Ohno, M.; Nishi, E.; Wang, H.; Li, S.; Kubota, M.; Yoshida, Y.; Matsutani, T.; Mine, S.; Machida, T.; Takemoto, M.; Yamagata, H.; Hayashi, A.; Yokote, K.; Kobayashi, Y.; Takizawa, H.; Kuroda, H.; Shimada, H.; Iwadate, Y.; Hiwasa, T. JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases. Preprints 2024, 2024011206. https://doi.org/10.20944/preprints202401.1206.v1

Abstract

Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.

Keywords

JMJD6; ischemic stroke; acute myocardial infarction; diabetes mellitus; atherosclerosis; esophageal cancer; diagnosis; autoantibody

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.